TEPH: Telaglenastat Efficacy in Pulmonary Hypertension

NCT ID: NCT07223528

Last Updated: 2025-12-11

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 28 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-02-28
• Study Completion Date: 2028-09-25

Brief Summary

The research study is being conducted to evaluate the effectiveness of a drug called Telaglenastat in adults diagnosed with Pulmonary Hypertension (PH). PH is a progressive condition that affects the arteries in the lungs, specifically the pulmonary arteries, which carry blood from the right side of the heart to the lungs. Telaglenastat is not currently approved by the Food and Drug Administration for the treatment of PH. However, the study investigators believe that Telaglenastat may help lower blood pressure in the lungs and improve both heart and lung function. It is important to note that the drug will not be available to participants once the study concludes.

Detailed Description

The study will consist of the following visits:

1. Screening Visit (30-60 mins)

• Consenting
• Medical history, physical exam, lab tests (blood, urine)
• Review of past heart/lung records
• Surveys

2. Baseline Visit (Visit 2, 2-3 hrs)

• Physical exam, 6-minute walk test
• Echo, Right Heart Catheterization (RHC)
• High-Resolution CT (HRCT) & Pulmonary Function Tests (PFTs) if applicable
• Lab tests, ECG, glutamine blood sample
• Surveys

3. Treatment Phase (Visits 3-6, Weeks 1,2,4,8) Telaglenastat 800 mg/twice daily

Short visits (30 mins) for:

• Physical Exam
• Surveys
• Labs

4. Visit 7 End of Treatment (week 12, 2-3 hours) include the following:

• Physical Exam
• 6 Minute Walk Test
• Echo/RHC/ECG
• HRCT/PFT group 3
• Labs
• Surveys

• Optional Extension (Visits 8-12, Weeks 13-24) Same procedures as initial 12 weeks Final visit includes full reassessment

Conditions

Pulmonary Hypertension

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Open-Label Telaglenastat Arm

Group Type: EXPERIMENTAL

Telaglenastat

Intervention Type: DRUG

The participant will need to come in for a screening visit prior prescribing the medication to confirm eligibility. The visit will include physical exams, labs, right heart cath, and maybe pulmonary function test and chest imaging. Eligible participants will be taking 800 mg Telaglenastat (CB-839) by mouth with food twice a day for a total of 12 weeks. Participants will need to come in for study related visits during this time. At the end of 12 months period, we will need to repeat same activities we did prior to prescribing to medication. Pending FDA approval, eligible participants may continue Telaglenastat for an additional 12 weeks.

Interventions

Telaglenastat

The participant will need to come in for a screening visit prior prescribing the medication to confirm eligibility. The visit will include physical exams, labs, right heart cath, and maybe pulmonary function test and chest imaging. Eligible participants will be taking 800 mg Telaglenastat (CB-839) by mouth with food twice a day for a total of 12 weeks. Participants will need to come in for study related visits during this time. At the end of 12 months period, we will need to repeat same activities we did prior to prescribing to medication. Pending FDA approval, eligible participants may continue Telaglenastat for an additional 12 weeks.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male or female age 18-75 years old.

2. Able to provide written informed consent.

3. Able to comply with study procedures, able to undergo cardiac catheterization and exercise testing.

4. Patients will be identified with PH Group 1-4 PH by an expert clinician in the UPMC Comprehensive Care Center for Pulmonary Hypertension.

5. For Group 1, 3, and 4 PH, prior right heart catheterization (RHC) should show documented diagnosis of precapillary PH at mean pulmonary arterial pressure (mPAP > 20 mm Hg, PCWP < 15 mm Hg, and PVR > 4 WU) within 1 year of randomization. If patient doesn't have RHC within 1 year, we will repeat RHC at baseline visit. For Group 2 PH, prior right heart catheterization (RHC) should show mean pulmonary arterial pressure mPAP > 20 mm Hg and PVR > 4 WU within one year of randomization. If patient don't have RHC within 1 year we will repeat RHC at baseline visit.

6. Minimum pulmonary vascular resistance (PVR) of > 4 Wood units by RHC at screening within last 6 months on at least one month of stable medical therapy.

7. Symptomatic PH classified as WHO functional class II or III.

8. Body mass index (BMI) 18 to 40 kg/m² at Screening. If BMI is > 35 kg/m², subject chest circumference should be < 65 inches (165 cm).

9. 6-minute walk distance (6MWD) ≥ 100 meters (m) and < 550 m at screening.

10. For Group 1 PH, patients on SOC medical treatment for PH with vasodilators or Sotatercept are required to have been receiving a stable dose for at least 3 months before undergoing randomization.

11. For Group 2 PH-HFpEF: Documented transthoracic echocardiogram or cardiac MRI with LV ejection fraction > 50% within 6 months of enrollment, along with meeting at least one of the three criteria by echocardiographic/MRI: (1) Diastolic dysfunction, (2) Left atrial enlargement (LA diameter > 3.6 cm), or (3) Prior right heart catheterization data indicating PCWP > 15 mm Hg. Stable heart failure therapy for at least 30 days.

12. For Group 3 PH-ILD, documented diagnosis of interstitial lung disease (diffuse parenchymal lung disease) by high resolution lung CT scan within 6 months of randomization. Patients with Group 3 PH with connective tissue disease should have confirmed baseline FVC < 70% within 6 months of randomization. For subjects with a history of lobectomy or pneumonectomy, and for whom there are no population-based normalization methods, assessment based on residual lung volume will be permitted to assess eligibility. Patients receiving drug treatment (i.e., pirfenidone or nintedanib) for their underlying lung disease or pulmonary hypertension (i.e., inhaled Treprostinil) should receive a stable dose for at least 30 days before undergoing randomization.

13. For Group 4 PH (CTEPH) eligible patients will have V/Q scan or CT scan with contrast demonstrating chronic thromboembolic disease in the pulmonary vasculature at least 6 months after most recent pulmonary embolus and with right heart catheterization within one year of enrollment. If patient doesn't have RHC within 1 year, we will repeat RHC at baseline visit. Eligible patients will include those with inoperable CTEPH or at least 6 months post-surgery with persistent thromboembolic disease. Patients receiving approved therapies for pulmonary hypertension are required to have been receiving a stable dose for at least 30 days before undergoing randomization.

14. Women of childbearing potential must be willing and able to practice medically acceptable effective contraception during the study and continuing contraception for 30 days after their last dose of study drug. Women who are surgically sterile or those who are post-menopausal for at least 2 years are not considered to be of childbearing potential. Men who are not sterile must also agree to use contraception.

Exclusion Criteria

1. For Group 2 PH-HFpEF patients:

• With clinically decompensated heart failure
• Uncontrolled hypertension (SBP > 160 mm Hg, DBP > 90)
• Echocardiographic/MRI
• Evidence of moderate-severe mitral regurgitation or mitral stenosis within 6 months of enrollment

2. Group 3 PH-ILD, patients receiving approved therapies other than inhaled Treprostinil for PAH within 60 days before randomization are not eligible for enrollment.

3. Group 1 PH, patients naïve to medical treatment for PH are not eligible for enrollment.

4. History of lung reduction surgery or likely to undergo lung transplantation within the next 6 months.

5. Enrolled in, or planned participation in, device or other interventional clinical studies or cardio-pulmonary rehabilitation programs, based upon exercise within 90 days of Screening or during study participation.

6. Patients with other secondary causes of PH including, but not limited to, left or right heart failure, valvular heart disease, chronic obstructive lung disease, atrial septal defect with left to right shunt, and sleep apnea will be excluded if it was the primary cause of PAH.

7. Diagnosed with significant (≥ 2+ regurgitation) mitral regurgitation or aortic regurgitation valvular disease

8. Uncontrolled hypertension (SBP > 160 mm Hg, DBP > 90)

9. Left ventricular ejection fraction (LVEF) < 45%

10. Adult congenital heart disease (ACHD)

11. Sustained systolic blood pressure (SBP) < 95 mmHg and/or diastolic blood pressure (DBP) < 50 mmHg (confirmed by duplicate seated readings) on at least 3 consecutive occasions (self-monitored or office) prior to or at Screening, or overt symptomatic hypotension

12. Sustained resting heart rate (HR) > 120 beats per minute (confirmed by duplicate assessments of office vital signs) or consecutive electrocardiogram (ECG) assessments on at least 3 consecutive occasions prior to or at Screening

13. Concomitant medical or psychiatric disorder, condition, history, or any other condition that, in the opinion of the Investigator, would either put the participant at risk or impair their ability to participate in or complete the requirements of the study or confound the objectives of the study

14. Concomitant medical disorder that is expected to limit the subject's life-expectancy to ≤ 1 year

15. Untreated, moderate to severe obstructive sleep apnea

16. Evidence of thrombocytopenia (platelets < 150,000/mm³), significant chronic thromboembolic disorder, or recent pulmonary embolism within 6 months prior to Screening

17. History of a bleeding disorder

18. Known porphyria, mitochondrial, or urea cycle disease

19. History of chronic pancreatic disease

20. Pregnant or lactating female

21. Active coronavirus disease 19 (COVID-19); however, those with previous COVID-19 are permitted

22. Participated in another investigational drug study within 30 days prior to Screening or is participating in a non-medication study which, in the opinion of the Investigator, would interfere with the study compliance or outcome assessments

23. Glomerular Filtration Rate (GFR) of < 30 mL/min/1.73m²

24. Significant liver dysfunction as measured by any one of the following at Screening (including subjects with acute or chronic hepatitis as well as subjects with own or family history of serious hepatitis, especially drug related):

• Alanine aminotransferase (ALT) > 2.0 × upper limit of normal (ULN)
• Aspartate aminotransferase (AST) > 2.0 × ULN
• Serum bilirubin ≥ 1.6 mg/dL or > 2.0 × ULN

25. Known history of substance abuse including alcohol abuse within the 1 year prior to Screening that in the opinion of the Investigator would impair the subject's ability to participate in or complete the requirements of the study

26. Any major surgical procedure or trauma within 30 days prior to Screening or planned surgical procedure during the study period.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Chan, Stephen, MD, PhD

OTHER

Sponsor Role: lead

Synhale Theraputics

UNKNOWN

Sponsor Role: collaborator

Responsible Party

Michael Risbano

Assistant Professor of Medicine

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Michael Risbano, MD

Role: PRINCIPAL_INVESTIGATOR

University of Pittsburgh

Locations

UPMC Presybeterian

Pittsburgh, Pennsylvania, United States

Countries

United States

Central Contacts

Yassmin A Al Aaraj, MPH

Role: CONTACT

yaa29@pitt.edu

14122668980

Michael Risbano, MD

Role: CONTACT

risbanomg@upmc.edu

14126922210

Facility Contacts

Yassmin Al Aaraj, MPH

Role: primary

yaa29@pitt.edu

4126479227

Other Identifiers

STUDY24070041

Identifier Type: -

Identifier Source: org_study_id